Assenagon Asset Management S.A. Boosts Stock Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Assenagon Asset Management increased its Gilead Sciences stake by 346.5% in the second quarter, purchasing 1.78 million additional shares and holding 2.29 million shares worth approximately $289 million. Institutional investors collectively own 83.67% of the company.
• Gilead reported second-quarter revenue of $7.8 billion, surpassing estimates, with product sales excluding Veklury up 10% year over year. Management raised its HIV growth outlook to 9%–10%, supported by strong HIV and PrEP demand.
• Despite the revenue beat, Gilead posted a $6.75 per-share loss due largely to acquisition-related costs and research spending. The discontinued Trodelvy-Keytruda study and declining Veklury sales add risks, although analysts maintain a consensus “Moderate Buy” rating and the company declared a $0.82 quarterly dividend.

Assenagon Asset Management S.A. increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 346.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,287,888 shares of the biopharmaceutical company's stock after purchasing an additional 1,775,452 shares during the quarter. Assenagon Asset Management S.A. owned 0.18% of Gilead Sciences worth $289,052,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Vermillion & White Wealth Management Group LLC lifted its stake in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 85 shares during the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $25,000. Quattro Advisors LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $26,000. Wealth Preservation Advisors LLC raised its holdings in shares of Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.8 billion, above the roughly $7.4 billion consensus estimate. Product sales excluding Veklury rose 10% year over year to $7.6 billion, led by HIV medicines and Trodelvy. GILD Q2 Earnings Beat
• Positive Sentiment: Management raised its HIV growth outlook to 9%–10% and highlighted rapid adoption of Yeztugo, its HIV prevention treatment. PrEP sales reportedly doubled to approximately $1 billion, supporting the view that HIV remains Gilead’s primary growth engine. Q2 Earnings Call Highlights
• Positive Sentiment: Several analysts remain constructive: Cantor Fitzgerald reiterated an Overweight rating with a $155 target, while Needham reaffirmed Buy with a $170 target. Gilead also declared its $0.82 quarterly dividend, providing continued income support.
• Neutral Sentiment: The quarter was described as operationally strong, but reported earnings guidance remains negative because of acquisition-related charges and elevated research spending. The company’s 2026 base-business sales outlook is approximately $29.8 billion–$30.1 billion.
• Negative Sentiment: Gilead posted a $6.75 per-share quarterly loss versus $2.01 of earnings a year earlier. The loss was driven largely by acquisition-related costs, increasing concern about near-term profitability despite the revenue beat. Strong Quarter Hidden Behind Ugly Earnings
• Negative Sentiment: MSD and Gilead discontinued a Phase III Trodelvy-Keytruda study after lacklustre interim data. The failure weakens expectations for expanding Trodelvy’s use in combination therapy and adds uncertainty to Gilead’s oncology growth strategy. Trodelvy-Keytruda Study Discontinued
• Negative Sentiment: Veklury sales continued to decline sharply, while AIDS Healthcare Foundation criticized Gilead’s HIV pricing and access policies. The controversy could create reputational or longer-term market-access risks. CEO Daniel O’Day’s planned sale of 15,000 shares was a minor additional negative signal.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Wall Street Zen cut shares of Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Cantor Fitzgerald reissued an "overweight" rating and issued a $155.00 target price on shares of Gilead Sciences in a report on Wednesday. The Goldman Sachs Group raised their price target on Gilead Sciences from $125.00 to $130.00 and gave the company a "neutral" rating in a research note on Friday, April 17th. Leerink Partners downgraded Gilead Sciences from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Finally, Royal Bank Of Canada upped their price objective on Gilead Sciences from $120.00 to $123.00 and gave the stock a "sector perform" rating in a research report on Wednesday. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $158.04.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 15,000 shares of the company's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the sale, the chief executive officer directly owned 592,133 shares of the company's stock, valued at $77,160,851.23. This represents a 2.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. This represents a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 82,000 shares of company stock valued at $10,641,790. Insiders own 0.30% of the company's stock.

Gilead Sciences Trading Down 0.7%

Shares of Gilead Sciences stock opened at $130.86 on Friday. The company has a current ratio of 1.14, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The company has a fifty day simple moving average of $129.43 and a 200-day simple moving average of $136.22. The stock has a market cap of $162.47 billion, a price-to-earnings ratio of -49.01 and a beta of 0.32. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion during the quarter, compared to analysts' expectations of $7.40 billion. During the same period in the previous year, the company earned $2.01 earnings per share. Gilead Sciences's quarterly revenue was up 10.6% compared to the same quarter last year. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.65 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences's payout ratio is presently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source